Clinical Trials Logo
  1. Home
  2. Gastroparesis
  3. NCT03603730

Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis

Gastroparesis Clinical Trial

Official title:
Modulation of Gastric Sensitivity and Accommodation by Vagal Nerve Stimulation

Clinical Trial Summary

Explore the effects of auricular transcutaneous vagal nerve stimulation (taVNS) on brain and stomach outcomes in functional dyspepsia and gastroparesis patients.

Clinical Trial Description

The primary aims of this study are to 1) investigate the effects of auricular transcutaneous vagal nerve stimulation (taVNS) on brain-gut signaling using a liquid meal test in functional dyspepsia (FD) and gastroparesis (GP) patients using combined gastric, autonomic and neuroimaging measures, and 2) evaluate the effectiveness of taVNS on FD and GP symptoms. A total of 25 FD and 25 GP patients will be enrolled in this study, both females and males, ranging between 18 and 65 years of age. There will be multiple study visits consisting of a screening, baseline testing, consumption of a liquid meal, and fMRI brain and gut imaging sessions. Visits will include active and inactive taVNS delivered to the outer ear at a moderate, non-painful level. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03603730
Study type Interventional
Source Massachusetts General Hospital
Contact Andrew Bolender, BA
Phone 617-643-4297
Email abolender@mgh.harvard.edu
Status Recruiting
Phase Early Phase 1
Start date November 30, 2018
Completion date March 30, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT03941288 - Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia Phase 2
Terminated NCT03285308 - A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01 Phase 3
Completed NCT00733551 - Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects. Phase 1
Completed NCT01650714 - Endoscopic Full Thickness Biopsy, Gastric Wall. N/A
Completed NCT01452815 - Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis Phase 2
Completed NCT01039974 - GSK962040 Drug-drug Interaction Study With Ketoconazole Phase 1
Terminated NCT04844190 - Use of EndoFLIP and Manometry Prior to G-POEM N/A
Enrolling by invitation NCT06215547 - Medtronic Enterra II Neurostimulator N/A
Completed NCT04026997 - A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis Phase 2
Completed NCT00562848 - A Study to Evaluate Safety, Side Effects, Muscle Activity and Speed of Gastric Emptying of GSK962040 Phase 1
Enrolling by invitation NCT04207996 - Vagus Nerve Response in Gastroparesis Patients
Completed NCT04607304 - ABCA2 GIRMS Analytical Validation Clinical Performance Study N/A
Recruiting NCT06068114 - Gastric Pathophysiology in Diabetes
Completed NCT03259841 - Ultrasound Assessment of Gastric Contents in Fasted Patient Undergoing Cholecystectomy
Active, not recruiting NCT04300127 - Pioglitazone for Idiopathic Gastroparesis Early Phase 1
Recruiting NCT01696734 - Domperidone in Treating Patients With Gastrointestinal Disorders Phase 3
Terminated NCT04635306 - 13C-Spirulina Nitrogen Content GEBT Study N/A
Withdrawn NCT02420925 - Effect of Celiac Plexus Block on Gastric Emptying and Symptoms Caused by Gastroparesis N/A
Recruiting NCT00777439 - Domperidone for Refractory Gastrointestinal Disorders N/A
Terminated NCT00760461 - Domperidone in Refractory Gastroparesis Phase 2